Tema Cardiovascular and Metabolics ETF (NASDAQ:HRTS) Short Interest Update

Tema Cardiovascular and Metabolics ETF (NASDAQ:HRTS) was the recipient of a significant decrease in short interest during the month of March. As of March 15th, there was short interest totalling 500 shares, a decrease of 28.6% from the February 28th total of 700 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average daily volume of 14,200 shares, the short-interest ratio is presently 0.0 days.

Hedge Funds Weigh In On Tema Cardiovascular and Metabolics ETF

An institutional investor recently raised its position in Tema Cardiovascular and Metabolics ETF stock. Sterling Investment Advisors Ltd. raised its position in Tema Cardiovascular and Metabolics ETF (NASDAQ:HRTS) by 5.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 167,703 shares of the company’s stock after acquiring an additional 9,008 shares during the quarter. Tema Cardiovascular and Metabolics ETF makes up about 1.2% of Sterling Investment Advisors Ltd.’s investment portfolio, making the stock its 24th largest holding. Sterling Investment Advisors Ltd. owned 7.29% of Tema Cardiovascular and Metabolics ETF worth $4,842,000 at the end of the most recent reporting period.

Tema Cardiovascular and Metabolics ETF Price Performance

HRTS stock traded down $0.14 during mid-day trading on Monday, reaching $29.33. The company had a trading volume of 21,233 shares, compared to its average volume of 12,559. Tema Cardiovascular and Metabolics ETF has a 52 week low of $28.56 and a 52 week high of $36.03. The company has a market capitalization of $67.46 million, a price-to-earnings ratio of 30.61 and a beta of 0.93. The stock has a 50 day simple moving average of $30.14 and a two-hundred day simple moving average of $31.34.

Tema Cardiovascular and Metabolics ETF Company Profile

The Tema Obesity & Cardiometabolic ETF (HRTS) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that concentrates on companies focused on the treatment of cardiovascular diseases and/or metabolic diseases from companies all around the world. Using both top-down and bottom-up stock selection, the fund identifies innovative companies deemed attractive.